Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-002 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT07658352Phase 2Not yet recruiting
- Sponsor
- Shanghai Chaoyang Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of HP-002 in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Chaoyang Pharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HP-002
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07658352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658352.